首页> Immunological medicine> Real-world effectiveness of belimumab and anifrolumab in systemic lupus erythematosus: comparable trends in disease activity and glucocorticoid reduction.

Real-world effectiveness of belimumab and anifrolumab in systemic lupus erythematosus: comparable trends in disease activity and glucocorticoid reduction.

导出 LinkOut

翻译打印收藏纠错

第一作者： Ryota,Sato

第一单位： Department of Rheumatology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.

作者： Ryota,Sato ^[1] ; Masaru,Shimizu ^[2] ; Yuya,Kondo ^[1] ; Kazushi,Maruo ^[3] ; Yuki,Kuroda ^[4] ; Hiroshi,Ebe ^[4] ; Mizuki,Yagishita ^[5] ; Naoto,Umeda ^[6] ; Seiji,Mogi ^[7] ; Ayako,Ohyama ^[1] ; Ayako,Kitada ^[1] ; Saori,Abe ^[1] ; Hiromitsu,Asashima ^[1] ; Haruka,Miki ^[1] ; Hiroto,Tsuboi ^[1] ; Isao,Matsumoto ^[1]

作者单位： Department of Rheumatology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan. ^[1] Department of Rheumatology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.;Department of Clinical Research and Regional Innovation, Institute of Medicine, University of Tsukuba, Tsukuba, Japan. ^[2] Department of Biostatistics, Institute of Medicine, University of Tsukuba, Tsukuba, Japan. ^[3] Department of Rheumatology, Ibaraki Seinan Medical Center Hospital, Sakai, Japan. ^[4] Department of Rheumatology, Tsukuba Gakuen Hospital, Tsukuba, Japan. ^[5] Department of Rheumatology, Tsuchiura Kyodo General Hospital, Tsuchiura, Japan. ^[6] Department of Rheumatology, Hitachi, Ltd. Hitachinaka General Hospital, Hitachinaka, Japan. ^[7]

关键词 Systemic lupus erythematosus anifrolumab belimumab comparative effectiveness